Inositec None

Inositec is a biotech company that was founded in 2015 as a spin-off of ETH Zurich. They specialize in developing a treatment for soft tissue calcification disorders using their proprietary Inositune platform of inositol phosphate (IP6) analogs. Their main focus is on addressing vascular and renal calcification disorders, including orphan indications.


Connections